Enter inventor name

José Maria Cid-Núñez

USPTO Granted Patents = 19 (Patent Applications = 5)

EPO Patents = 13 (Patent Applications = 10)

Average Co-Inventor Count = 3.6

ph-index = 4

Forward Citations = 61(Granted Patents)

Company Filing History:

15 out of 2,079

Janssen Pharmaceutica Nv

patents

4 out of 159

Janssen Pharmaceuticals, Inc.

where one patent can have more than one assignee

Years Active: 2010-2024

Loading Chart...

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12048696 - Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use (2024-07-30),

2. 11369606 - Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use (2022-06-28),

3. 11103506 - Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use (2021-08-31),

4. 10590131 - 1,2,4-triazolo[4,3-a]pyridine compounds and their use as positive allosteric modulators of mGluR2 receptors (2020-03-17),

5. 10584129 - Substituted 6,7-dihydropyrazolo[1,5-a]pyrazines as negative allosteric modulators of mGluR2 receptors (2020-03-10),

6. 10537573 - Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use (2020-01-21),

7. 10138237 - 1,2,4-triazolo[4,3-a]pyridine compounds and their use as positive allosteric modulators of mGluR2 receptors (2018-11-27),

8. 10106542 - Substituted 6,7-dihydropyrazolo[1,5-a]pyrazines as negative allosteric modulators of mGluR2 receptors (2018-10-23),

9. 9708315 - 1,2,4-triazolo[4,3-a]pyridine compounds and their use as positive allosteric modulators of MGLUR2 receptors (2017-07-18),

10. 9271967 - 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors (2016-03-01),

11. 9012448 - 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors (2015-04-21),

12. 8993591 - 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors (2015-03-31),

13. 8569267 - Tetracyclic tetrahydrofuran derivatives containing cyclic amine side chain (2013-10-29),

14. 8415347 - Substituted tetracyclic tetahydrofuran, pyrrolidine and tetrahydrothiophene derivatives (2013-04-09),

15. 8404729 - Heterocyclic tetracyclic tetrahydrofuran derivatives (2013-03-26),

Title: Innovations and Contributions of José Maria Cid-Núñez

Introduction

José Maria Cid-Núñez is a prominent inventor based in Toledo, Spain, known for his significant contributions to the field of pharmaceuticals. With an impressive portfolio of 19 patents, he has made considerable strides in the development of novel compounds that hold the potential for therapeutic applications.

Latest Patents

Among his latest patents are innovative combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2. These inventions aim to enhance the efficacy of treatments by utilizing specific compounds alongside synaptic vesicle protein 2A (SV2A) ligands. The inventive concepts focus on both positive allosteric modulators and orthosteric agonists, emphasizing their potential therapeutic use in various neurological conditions.

Career Highlights

José has worked at notable companies in the pharmaceutical industry, including Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc. His tenure at these organizations reflects his active role in advancing pharmaceutical innovations, particularly in medication development for neurological conditions.

Collaborations

Throughout his career, José has collaborated with talented professionals such as Andrés Avelino Trabanco-Suárez and Gregor James MacDonald. These partnerships have contributed to his success in patenting new inventions and fostering a collaborative environment for innovation.

Conclusion

In summary, José Maria Cid-Núñez exemplifies the spirit of innovation in the pharmaceutical sector. With his extensive patent portfolio and collaborative efforts among industry professionals, he continues to pave the way for advancements in medicine. His contributions have significant implications for therapeutic approaches to treating neurological disorders, establishing him as a noteworthy figure in the field of invention.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com